Trade Palisade Bio, Inc. - PALI CFD

Add to favourite

4.58

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.23

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Key Stats

Prev. Close*	5.02
Open*	5.94
1-Year Change*	212.63%
Day's Range*	4.88 - 5.95
52 wk Range	0.07-2.86
Average Volume (10 days)	2.02M
Average Volume (3 months)	123.43M
Market Cap	5.83M
P/E Ratio	0.22
Shares Outstanding	71.24M
Revenue	N/A
EPS	0.37
Dividend (Yield %)	N/A
Beta	1.80
Next Earnings Date	Mar 16, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	5.02	-0.99	-16.47%	6.01	6.07	4.87
Apr 17, 2024	6.53	0.36	5.83%	6.17	7.78	5.90
Apr 16, 2024	5.82	-2.99	-33.94%	8.81	9.59	5.31
Apr 15, 2024	4.13	0.05	1.23%	4.08	4.35	3.98
Apr 12, 2024	4.09	-0.22	-5.10%	4.31	4.32	3.83
Apr 11, 2024	4.32	0.10	2.37%	4.22	4.67	4.22
Apr 10, 2024	4.07	-1.00	-19.72%	5.07	5.07	4.07
Apr 9, 2024	5.39	-0.53	-8.95%	5.92	5.92	5.08
Apr 8, 2024	6.00	0.83	16.05%	5.17	7.12	5.07
Mar 28, 2024	0.39	0.00	0.00%	0.39	0.39	0.39
Mar 8, 2024	0.38	0.00	0.00%	0.38	0.38	0.38
Mar 7, 2024	0.38	0.00	0.00%	0.38	0.38	0.38
Mar 6, 2024	0.38	0.00	0.00%	0.38	0.38	0.38
Mar 5, 2024	0.38	0.00	0.00%	0.38	0.38	0.38
Mar 1, 2024	0.38	-0.01	-2.56%	0.39	0.40	0.38
Feb 29, 2024	0.39	0.00	0.00%	0.39	0.40	0.39
Feb 28, 2024	0.38	0.00	0.00%	0.38	0.38	0.38
Feb 27, 2024	0.38	0.00	0.00%	0.38	0.38	0.38
Feb 26, 2024	0.38	0.00	0.00%	0.38	0.39	0.38
Feb 23, 2024	0.38	-0.02	-5.00%	0.40	0.40	0.38

Palisade Bio, Inc. Events

Time (UTC)	Country	Event
Friday, May 10, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Palisade Bio Inc Earnings Release Q1 2024 Palisade Bio Inc Earnings Release Forecast - Previous -
Friday, June 7, 2024
Time (UTC) 17:00	Country US	Event Palisade Bio Inc Annual Shareholders Meeting Palisade Bio Inc Annual Shareholders Meeting Forecast - Previous -
Friday, August 9, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Palisade Bio Inc Earnings Release Q2 2024 Palisade Bio Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2021	2020	2019	2018	2017
Total revenue	0	0.01352	0.01539	0.26	0.26
Revenue		0.01352	0.01539	0.26	0.26
Total Operating Expense	42.261	10.6891	8.64709	8.51946	13.5671
Selling/General/Admin. Expenses, Total	9.307	8.67061	4.58564	4.55927	5.47101
Research & Development	2.43	2.01845	4.06145	3.96019	8.0961
Operating Income	-42.261	-10.6756	-8.6317	-8.25946	-13.3071
Interest Income (Expense), Net Non-Operating	20.635	0.02881	0.55795	3.34023	-1.55898
Other, Net	-4.99	-5.62009	-0.27791	-0.00539	-0.79991
Net Income Before Taxes	-26.616	-16.2668	-8.35165	-4.92462	-15.666
Net Income After Taxes	-26.616	-16.2668	-8.35165	-4.92462	-15.666
Net Income Before Extra. Items	-26.616	-16.2668	-8.35165	-4.92462	-15.666
Net Income	-26.616	-16.2668	-8.35165	-4.92462	-15.666
Income Available to Common Excl. Extra. Items	-26.616	-16.2668	-8.35165	-4.92462	-15.666
Income Available to Common Incl. Extra. Items	-26.616	-16.2668	-8.35165	-4.92462	-15.666
Diluted Net Income	-26.616	-16.2668	-8.35165	-4.92462	-15.666
Diluted Weighted Average Shares	9.30977	2.31155	0.36625	0.12631	0.10887
Diluted EPS Excluding Extraordinary Items	-2.85893	-7.03721	-22.8034	-38.9883	-143.893
Diluted Normalized EPS	0.41977	-7.03721	-22.8034	-38.9883	-143.893
Unusual Expense (Income)	30.524

	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021
Total revenue	0	0	0	0	0
Total Operating Expense	3.888	4.027	3.016	32.858	2.36
Selling/General/Admin. Expenses, Total	2.929	3.227	2.392	2.427	1.261
Research & Development	0.959	0.8	0.624	0.314	0.692
Unusual Expense (Income)	0	0	0	30.117	0.407
Operating Income	-3.888	-4.027	-3.016	-32.858	-2.36
Interest Income (Expense), Net Non-Operating	0.792	5.089	12.738	4.478	-1.67
Other, Net	-1.109	0.011	-1.635	-3.366	0
Net Income Before Taxes	-4.205	1.073	8.087	-31.746	-4.03
Net Income After Taxes	-4.205	1.073	8.087	-31.746	-4.03
Net Income Before Extra. Items	-4.205	1.073	8.087	-31.746	-4.03
Net Income	-4.205	1.073	8.087	-31.746	-4.03
Income Available to Common Excl. Extra. Items	-4.205	1.073	8.087	-31.746	-4.03
Income Available to Common Incl. Extra. Items	-4.205	1.073	8.087	-31.746	-4.03
Diluted Net Income	-4.205	1.073	8.087	-31.746	-4.03
Diluted Weighted Average Shares	16.2237	13.5328	12.1068	8.9842	7.43177
Diluted EPS Excluding Extraordinary Items	-0.25919	0.07929	0.66797	-3.53354	-0.54227
Dividends per Share - Common Stock Primary Issue	0		0	0	0
Diluted Normalized EPS	-0.25919	0.07929	0.66797	-0.18132	-0.4875

Annual
Quarterly

	2021	2020	2019	2018	2017
Total Current Assets	12.374	12.8808	5.64688	6.50839	12.4488
Cash and Short Term Investments	10.495	10.5292	5.11492	5.78711	11.6749
Cash & Equivalents	10.495	10.5292	5.11492	5.78711	6.67494
Short Term Investments				0	5
Total Receivables, Net	0.15	0.11628	0.02106	0.358	0.37159
Accounts Receivable - Trade, Net	0	0.11628	0.02106	0.29406	0.3128
Prepaid Expenses	1.703	1.39979	0.5109	0.36329	0.40227
Total Assets	12.512	13.0491	6.58389	7.68445	13.8845
Property/Plant/Equipment, Total - Net	0.112	0.01078	0.04104	0.09031	0.17289
Property/Plant/Equipment, Total - Gross			0.99145		0.99481
Accumulated Depreciation, Total			-0.95042		-0.82193
Intangibles, Net		0.14713	0.66894	0.76354	0.88346
Note Receivable - Long Term			0	0.29824	0.36546
Other Long Term Assets, Total	0.026	0.01044	0.22704	0.02397	0.01385
Total Current Liabilities	2.496	3.20593	1.22476	1.05117	1.51457
Payable/Accrued		0.64935	0.82441	0.83256	0.87507
Accrued Expenses	1.086	2.32224	0.13569	0	0.41863
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0.087				0
Other Current Liabilities, Total		0.23434	0.26467	0.2186	0.22088
Total Liabilities	5.147	3.28123	1.4579	1.6349	5.36933
Total Long Term Debt	0	0	0	0	0
Long Term Debt	0
Other Liabilities, Total	2.651	0.0753	0.23314	0.58373	3.85476
Total Equity	7.365	9.76792	5.12599	6.04955	8.51513
Preferred Stock - Non Redeemable, Net	0.002	0.002	0.002	0.01	0.01
Common Stock	0.143	0.17296	0.03867	0.18205	0.1516
Additional Paid-In Capital	101.862	247.836	227.067	219.482	217.05
Retained Earnings (Accumulated Deficit)	-94.642	-238.242	-221.976	-213.624	-208.699
Other Equity, Total		-0.00073	-0.00619	-0.00041	0.00263
Total Liabilities & Shareholders’ Equity	12.512	13.0491	6.58389	7.68445	13.8845
Total Common Shares Outstanding	14.2392	2.88268	0.64442	0.15171	0.12634
Total Preferred Shares Outstanding	0.2	0.2	0.2	1	1
Other Current Assets, Total	0.026	0.83548
Accounts Payable	1.323

	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021
Total Current Assets	8.258	12.374	16.092	14.725	8.7556
Cash and Short Term Investments	6.644	10.495	14.104	12.653	6.56095
Cash & Equivalents	6.644	10.495	14.104	12.653	6.56095
Total Receivables, Net	0.086	0	0	0.059	0.02526
Accounts Receivable - Trade, Net		0	0	0.059	0.02526
Prepaid Expenses	1.42	1.879	1.988	2.013	1.30869
Other Current Assets, Total	0.108				0.8607
Total Assets	8.35	12.512	16.274	14.949	8.91492
Property/Plant/Equipment, Total - Net	0.066	0.112	0.156	0.198	0.00724
Intangibles, Net					0.14164
Other Long Term Assets, Total	0.026	0.026	0.026	0.026	0.01044
Total Current Liabilities	1.864	2.496	2.92	3.85	1.01493
Payable/Accrued					0.52091
Accrued Expenses	0.717	1.086	0.969	1.303	0.31626
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total					0.17776
Total Liabilities	3.558	5.147	12.354	24.393	1.18613
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	1.694	2.651	9.434	20.543	0.1712
Total Equity	4.792	7.365	3.92	-9.444	7.72879
Preferred Stock - Non Redeemable, Net	0.002	0.002	0.002	0.002	0.002
Common Stock	0.183	0.143	0.13	0.114	0.02883
Additional Paid-In Capital	103.454	101.862	99.503	94.242	248.228
Retained Earnings (Accumulated Deficit)	-98.847	-94.642	-95.715	-103.802	-240.527
Other Equity, Total					-0.00278
Total Liabilities & Shareholders’ Equity	8.35	12.512	16.274	14.949	8.91492
Total Common Shares Outstanding	18.2335	14.2392	12.9299	11.3987	2.88262
Total Preferred Shares Outstanding	0.2	0.2	0.2	0.2	0.2
Accounts Payable	1.147	1.323	1.383	1.406
Current Port. of LT Debt/Capital Leases	0	0.087	0.568	1.141
Long Term Debt		0	0	0

Annual
Quarterly

	2021	2020	2019	2018	2017
Net income/Starting Line	-26.616	-16.2668	-8.35165	-4.92462	-15.666
Cash From Operating Activities	-14.773	-9.02513	-7.25568	-7.69242	-13.4162
Cash From Operating Activities	0.002	0.09227	0.14386	0.1858	0.28921
Non-Cash Items	16.597	6.19578	0.74383	-2.61672	4.11447
Cash Taxes Paid					0
Changes in Working Capital	-4.756	0.95364	0.20829	-0.33688	-2.15385
Cash From Investing Activities	-0.054		0	4.99829	-0.09405
Capital Expenditures			0	-0.00171	-0.09405
Other Investing Cash Flow Items, Total	-0.054		0	5	0
Cash From Financing Activities	24.609	14.4659	6.58951	1.81423	4.99078
Financing Cash Flow Items	-0.218
Issuance (Retirement) of Stock, Net	25.01	14.6982	6.55308	1.828	8.73602
Issuance (Retirement) of Debt, Net	-0.183	-0.2323	0.03643	-0.01377	-3.74524
Foreign Exchange Effects		-0.00119	-0.00602	-0.00793	-0.00058
Net Change in Cash	9.782	5.4396	-0.67219	-0.88783	-8.52001

	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021
Net income/Starting Line	-4.205	-26.616	-27.689	-35.776	-2.28508
Cash From Operating Activities	-3.764	-14.773	-11.718	-8.972	-3.94124
Cash From Operating Activities	0.001	0.002	0.002	0.002	0.00903
Non-Cash Items	0.72	16.597	21.342	32.167	0.3439
Changes in Working Capital	-0.28	-4.756	-5.373	-5.365	-2.00908
Cash From Investing Activities	0	-0.054	-0.054	0.294	0
Other Investing Cash Flow Items, Total	0	-0.054	-0.054	0.294	0
Cash From Financing Activities	-0.087	24.609	25.163	20.618	0
Issuance (Retirement) of Stock, Net		25.01	25.01	19.801	0
Issuance (Retirement) of Debt, Net	-0.087	-0.183	0.301	0.965	0
Foreign Exchange Effects					-0.00104
Net Change in Cash	-3.851	9.782	13.391	11.94	-3.94228
Capital Expenditures				0
Financing Cash Flow Items		-0.218	-0.148	-0.148

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Palisade Bio, Inc. Company profile

About Palisade Bio Inc

Palisade Bio, Inc, formerly Seneca Biopharma, Inc., is a biopharmaceutical company. The Company is focused on developing therapies that helps patients with acute and chronic gastrointestinal problems from post-operative digestive enzyme damage. Its product candidate, LB1148, is a Phase III-ready protease inhibitor which is developed to reduce abdominal adhesions and help restore bowel function following surgery. It is engaged in developing oral product candidates to treat conditions driven by protease (intestinal digestive enzymes) escaping the intestines, including surgical problems and inflammatory conditions. Its LB1148 is an oral formulation of a serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Palisade Bio Inc revenues decreased from $11K to $0K. Net loss increased from $11.8M to $27.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest expense increase from $14K to $2.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$7.31 to -$3.41.

Equity composition

Common Stock $.01 Par, 03/11, 150M auth., 48,366,304 shares issd. Insiders & Strategic holders own 13.61%. IPO:1/07, 16.3M shares @ $1 per Share.

Industry:

Biotechnology & Medical Research (NEC)

7750 El Camino Real, Suite 5200
92009

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024